What is Cystinosis

Cystinosis is a rare, life-long genetic metabolic disorder characterized by the abnormal accumulation of the amino acid cystine within the body’s cells, which leads to widespread tissue and organ damage.

Understanding the Condition

In individuals with Cystinosis, a defect in a specific transport protein prevents cystine from leaving the lysosome, the cell’s "recycling center." As cystine builds up, it forms microscopic crystals that slowly destroy cells throughout the body. Because these crystals accumulate in almost every organ, Cystinosis is considered a systemic disease that requires multi-specialty medical management.

Affected Systems and Subtypes

The kidneys are typically the first organs affected, often leading to Fanconi syndrome, where essential nutrients are lost in the urine. Over time, the eyes, thyroid, muscles, pancreas, and central nervous system may also be impacted by crystal deposition. Clinical classification is generally divided into three types:

• Infantile (nephropathic) Cystinosis: The most common and severe form, typically presenting in early infancy.


• Juvenile (intermediate) Cystinosis: Presents later in childhood with milder kidney involvement.


• Ocular (non-nephropathic) Cystinosis: Primarily affects the eyes, with little to no kidney involvement.

Prevalence and Demographics

Cystinosis is an ultra-rare condition, with an estimated global prevalence of approximately 1 in 100,000 to 200,000 individuals. It is inherited in an autosomal recessive pattern, meaning both parents must carry a mutation in the CTNS gene to pass it to their child. It affects males and females equally across all ethnic and geographic populations, though specific founder mutations have been observed in certain regions.

Key Differentiators

While many metabolic disorders cause developmental delays, the hallmark of Cystinosis is the pathognomonic presence of corneal cystine crystals, which can be visualized by an ophthalmologist using a slit-lamp examination. Unlike other storage diseases, this condition is specifically managed through cystine-depleting therapies that aim to lower intracellular cystine levels and preserve organ function.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• OMIM (Online Mendelian Inheritance in Man)


• Cystinosis Research Network